Replies to post #15617 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

The B [i.e. phase-2] part of the necuparanib trial in combination with nab-paclitaxel and gemcitabine doesn't have many eligibility roadblocks and only needs a total of 180 pts.

MNTA’s all-comers approach could paradoxically be impeding enrollment insofar as many trials in pancreatic cancer are targeted to specific oncogenes, and patients are more apt to select a trial tailored to their disease subtype.

[DewDiligence]

Just to be clear: 180 is the expected number of newly enrolled patients in the randomized phase-2 portion of the trial; i.e., it does not include "re-used" patients from the phase-1 portion.